According to Zacks, “Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado. “
A number of other research firms have also recently weighed in on NVLS. HC Wainwright restated a buy rating on shares of Nivalis Therapeutics in a report on Monday, August 8th. Raymond James Financial Inc. began coverage on Nivalis Therapeutics in a report on Tuesday, September 13th. They set an outperform rating and a $20.00 target price on the stock. Cowen and Company reiterated a buy rating on shares of Nivalis Therapeutics in a report on Monday, August 1st. Finally, Piper Jaffray Cos. reiterated a buy rating and set a $16.00 target price on shares of Nivalis Therapeutics in a report on Tuesday, August 30th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $13.75.
Shares of Nivalis Therapeutics (NASDAQ:NVLS) opened at 7.46 on Wednesday. The stock has a 50 day moving average price of $7.52 and a 200-day moving average price of $5.36. Nivalis Therapeutics has a 52 week low of $3.68 and a 52 week high of $9.45. The firm’s market capitalization is $115.65 million.
Nivalis Therapeutics (NASDAQ:NVLS) last released its quarterly earnings results on Monday, August 1st. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.03. Equities analysts anticipate that Nivalis Therapeutics will post ($2.29) earnings per share for the current year.
In other Nivalis Therapeutics news, EVP David Malcom Rodman sold 5,820 shares of the stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $7.96, for a total transaction of $46,327.20. Following the transaction, the executive vice president now owns 18,056 shares of the company’s stock, valued at approximately $143,725.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 3.00% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. BVF Inc. IL raised its position in shares of Nivalis Therapeutics by 29.4% in the first quarter. BVF Inc. IL now owns 1,546,743 shares of the company’s stock worth $6,450,000 after buying an additional 351,730 shares in the last quarter. State Street Corp raised its position in shares of Nivalis Therapeutics by 4.5% in the first quarter. State Street Corp now owns 44,495 shares of the company’s stock valued at $186,000 after buying an additional 1,900 shares during the period. Opaleye Management Inc. purchased a new position in shares of Nivalis Therapeutics during the first quarter valued at $417,000. Sabby Management LLC raised its position in shares of Nivalis Therapeutics by 31.5% in the first quarter. Sabby Management LLC now owns 662,058 shares of the company’s stock valued at $2,761,000 after buying an additional 158,463 shares during the period. Finally, Paloma Partners Management Co purchased a new position in shares of Nivalis Therapeutics during the second quarter valued at $105,000. 83.12% of the stock is currently owned by institutional investors.
Nivalis Therapeutics Company Profile
Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.